

# Other Manufacturing Functions: Recovery, Storage, Labeling

*NEW PARADIGM FOR TISSUE REGULATION*

*February 1-3, 2004*

*Dallas, Texas*

Anita Richardson

Assistant to the Director for Policy

Office of Compliance and Biologics Quality



# Other Manufacturing Functions

- *Recovery*
- *Labeling Controls*
- *Storage*
- *Labeling*

# Recovery

## 21 CFR 1271.3(ii)

*Obtaining from a human donor cells or tissues that are intended for use in human implantation, transplantation, infusion, or transfer.*

# Recovery

## 21 CFR 1271.215

If you are an establishment that recovers HCT/Ps, you must recover each HCT/P in a way that does not cause contamination or cross-contamination during recovery, or otherwise increase the risk of the introduction, transmission, or spread of communicable disease through the use of the HCT/P

# Recovery

## 21 CFR 1271.215

(Continued)

- You must establish and maintain procedures for cell and tissue recovery.
- [No comments were received on this provision]

# Labeling Controls

## 21 CFR 1271.250

### a. General

- Establish and maintain procedures to control the labeling of HCT/Ps.
- Design procedures to ensure proper HCT/P identification and to prevent mix-ups

# Labeling Controls

## 21 CFR 1271.250

### b. Verification

- Procedures must include verification of label accuracy, legibility, and integrity.

# Labeling Controls

## 21 CFR 1271.250

### c. Labeling Requirements

Procedures must ensure that each HCT/P is labeled in accordance with all applicable labeling requirements, including those in

- 1271.55 Records that accompany; records to be retained
- 1271.60 Requirements that apply before DE determination
- 1271.65 Storage of HCT/P from ineligible donor
- 1271.90 Exceptions from DE and labeling requirements
- 1271.290 Facilities
- 1271.370 Labeling



# Labeling Controls

## 21 CFR 1271.250

c. (continued)

Procedures must ensure that each HCT/P made available for distribution is accompanied by documentation of the donor eligibility determination as required under under 1271.55

# Labeling Controls

## 21 CFR 1271.250

### [Comments 104 & 105]

- Comments asserted these requirements as applied to in-house distribution are too burdensome
- Asserted the type of info is exorbitant for the ID of individual products
- FDA disagreed; believing it is important for the physician to have accurate, specific info
- However, FDA modified 21 CFR 1271.55 to mod the records requirement

# Storage

## 21 CFR 1271.3(jj)

*Storage means holding HCT/Ps for future processing and/or distribution.*



# Storage

## 21 CFR 1271.260

- a. Control Storage areas to prevent,
  - (1) Mix-ups, contamination, and cross-contamination of HCT/Ps, supplies and reagents
  - (2) An HCT/P from being improperly made available for distribution
- b. Temperature. You must store HCT/Ps at an appropriate temperature

# Storage

## 21 CFR 1271.260

### [Comment 106]

- Asked whether establishments must validate storage temp and period requirements in PR.
- Noted many have been established by the industry based on experience
- FDA agrees establishments may follow industry std where the std meet regulatory requirements
- Industry may establish and validate their own criteria

# Storage

## 21 CFR 1271.260

- c. Expiration date. *Where appropriate*, you must assign an exp date based on the following factors:
  - 1. HCT/P Type
  - 2. Processing,- incl. method of preservation
  - 3. Storage conditions
  - 4. Packaging

# Storage

## 21 CFR 1271.260

### d. Corrective Action.

You must take and document corrective action whenever proper storage conditions are not met.

# Storage

## 21 CFR 1271.260

### [Comment 107]

- Two comments stated the safe duration of cryopreservation for hematopoietic stem/prog cells is unknown and will take years to validate
- FDA discusses exp date for “fresh” HCT/Ps, and those thawed after cryopreservation;
- If no scientific data exist, then no exp date is required at this time;
- FDA encourages further studies



# Storage

## 21 CFR 1271.260

- e. Acceptable temperature limits. You must:
  - Establish acceptable temperature limits for storage for each step of mfr. to inhibit growth of infectious agents
  - Maintain and record temperatures
  - Periodically review recorded temps

Subpart E  
Additional Requirements  
Labeling  
21 CFR 1271.370

# Subpart E -Additional Requirements Labeling

## 21 CFR 1271.370

Apply in addition to to 1271.55,1271.60,  
1271.65 and 1271.90

- a. HCT/P made available for  
distribution must be labeled clearly and  
accurately.

# Subpart E -Additional Requirements

## Labeling

### 21 CFR 1271.370

b. Following information must appear on the HCT/P label:

1. Distinct ID code affixed to HCT/P container and assigned in accordance with 1271.290(c) [Tracking]
2. Description and type of HCT/P
3. Expiration date, if any
4. Warnings required under 1271.60(d)(2), 1271.65(b)(2) or 1270.90(b), if applicable

# “Label”

## [Comment 146]

- The term “label” in this subpart means either:
  1. Affix to the HCT/P container, or
  2. Attach a tie-tag with the appropriate info to the container

# Additional Requirements Labeling

## 21 CFR 1271.370

### [Comment 147]

- One comment stated that guidance is needed on “warnings”
- In response, FDA added 1271.370(b)(4), which lists as information the warnings required under 1271.60, 1271.65, or 1271.90, as applicable
- Pertaining to communicable disease risks

# Additional Requirements Labeling

## 21 CFR 1271.370

[Comment 147]

- FDA now requires warning statements related to informing the recipient about certain unusual circumstances
- e.g. “WARNING: Advise patient of communicable disease risk” when HCT/P is distributed before completion of DE determination

# Subpart E -Additional Requirements

## Labeling

21 CFR 1271.370

- c. Information must appear on the HCT/P label or *accompany* the HCT/P:
  - 1. Name and address of establishment that makes release determin. and makes HCT/P available for distrib.
  - 2. Storage temperature
  - 3. Other warnings, *where appropriate*
  - 4. Instructions for use when related to the prevention, introduction, transmission or spread of comm. diseases



# Additional Requirements

## Labeling

21 CFR 1271.370

- See Comments 149, 150, 151
- FDA has removed “claims” provision from 1271.370
- FDA has added the terms “repair” and “reconstruction” to the definition of “homologous use” at 1271.3c.